Status:
COMPLETED
Evaluation Study of Fear of Cancer Recurrence: Detection, Measure and Risk Factors in Lymphoma Survivorship
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Fondation de l'Avenir
Conditions:
Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Cancer survivorship has become an important aspect of oncology research due to the risk of physical and psychosocial complications. These latter concerns 50 % of patients. So, the aim of this research...
Detailed Description
Indeed, in a recent work published by our team, several complication types in cancer survivorship has been identified: physical but also psychosocial disorders, which can lead to quality of life deter...
Eligibility Criteria
Inclusion
- Complete response of lymphoma (Cheson criteria 2007) after initial treatment
- Malin lymphoma (Hodgkin or not) treated with anthracyclines for at least 6 cycles : Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) or BEACOPP, Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) et Rituximab (R-CHOP), miniCHOP et RminiCHOP, RACVBP having received or not an intensification with autologous hematopoietic stem cell transplantation in first-line
- Registered the consent to be included in this study
Exclusion
- Person under judicial protection
Key Trial Info
Start Date :
November 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 2 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03260855
Start Date
November 28 2017
End Date
March 2 2023
Last Update
August 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Universitaire du Cancer de Toulouse CHU de Toulouse
Toulouse, France, 31000